PHARNEXT announces €8 million roundThursday, 9 February 2012  We are pleased to announce an additional €8 million round of financing, as a private placement. This takes the total raised in 2011 to €10.5 million.Press Release (EN or FR) Back to previous page Read more |
Patient recruitment for CMT completedTuesday, 22 November 2011  PHARNEXT has completed patient recruitment for its Phase II clinical trial of PXT3003 (the company’s first Pleodrug™) in Charcot-Marie-Tooth disease. Press Release (EN or FR) Back to previous page. Read more |
PHARNEXT announces a €2.5 million roundThursday, 8 September 2011  We are pleased to announce a €2.5 million round of financing. Parinvest, Jean-Charles Naouri's holding company, invests in Pharnext. For more details, please read Press Release (EN or FR). Back to previous page Read more |
Pharnext moved to new locationWednesday, 1 June 2011 We are pleased to announce that Pharnext moved to brand new facilities located in Issy les Moulineaux, in the very close suburbs of Paris, since early June 2011.Please note our new contact details: Pharnext11 rue des peupliers92130 Issy les MoulineauxFrance+33 1 41 09 22 30 Back to previous ... Read more |
Pharnext in Phase II trial for CMT-1AMonday, 6 December 2010 Pharnext receives clinical trial authorization for a phase II study with the first drug generated by its Pleotherapy technology; The French Agency for Healthcare Product Safety (AFSSAPS) authorizes the trial in patients suffering from Charcot-Marie-Tooth disease type 1A. Pharnext's first PleodrugT... Read more |
Pharnext in Alzheimer's diseaseWednesday, 24 November 2010  OSEO awards a €10.4 million funding package to Pharnext and partners in the field of Alzheimer's disease to run the DIPPAL project for early detection and Pleotherapy of the disease. Pharnext is the project leader and will run the therapeutic applications. Biosystems International, Bordeaux Hosp... Read more |
Pharnext raises €4.8 MThursday, 10 June 2010 Pharnext announces that it had closed a €4.8-million Series A round of funding on June 3rd. Part of the fresh investment was provided by Pharnext's co-founding investor Truffle Capital, which remains the majority shareholder. The remaining were contributed by Aurinvest Capital 2, Financière Bosc... Read more |
Pharnext & Ipsen AgreementMonday, 15 June 2009  PHARNEXT and Ipsen concludedan exclusive R&D and marketing agreement in June 2009 for the treatment of CMT (Charcot-Marie-Tooth) disease, issued from the Pleotherapy technology developed by PHARNEXT. Pharnext will carry out the development of Pleotherapy-based drug candidates for the treatme... Read more |